Stockscreener 앱 받기
0.7911
3.70%
-0.0304
시간 외 거래:
.81
0.0189
+2.39%
Allarity Therapeutics Inc 주식(ALLR)의 최신 뉴스
Allarity Therapeutics Inc (ALLR) Is A Good Stock To Invest In - stocksregister.com
Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Bright Minds Biosciences (NASDAQ:DRUG) - Defense World
US Stocks Likely To Open Mixed After Disappointing Q1 Performance: 'April Does Better After A Weak Q1,' Says Expert - Benzinga
XPeng, Ultralife And 3 Stocks To Watch Heading Into Tuesday - Benzinga
Allarity Therapeutics, Inc. SEC 10-K Report - TradingView
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - GlobeNewswire
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update - The AM Reporter
Allarity Therapeutics (NASDAQ:ALLR) Trading 11% Higher – Still a Buy? - Defense World
ALLR Shareholders are Encouraged to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire
Allarity Therapeutics probes potential stock manipulation By Investing.com - Investing.com Australia
Allarity Therapeutics probes potential stock manipulation - Investing.com
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares - GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Allarity Takes Bold Action Against Market Manipulation: Launches High-Tech Trading Investigation - Stock Titan
Investigation announced for Long-Term Investors in shares - openPR.com
ALLR Shareholders Are Encouraged To Join Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm - MENAFN.COM
Allarity Therapeutics Announces Presentation of Phase 2 - GlobeNewswire
Allarity Therapeutics Presents Positive Phase 2 Data For Stenoparib In Advanced Ovarian Cancer - Nasdaq
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology - The Manila Times
Allarity reports promising ovarian cancer trial results - Investing.com
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in ... - The Bakersfield Californian
Breakthrough: New Cancer Drug Achieves 10-Month Complete Response in Advanced Ovarian Cancer Patients - StockTitan
ALLR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm! - ACCESS Newswire
ALLR Investors Have Opportunity to Join Allarity Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm - PrimePublishers.com
Allarity Therapeutics settles SEC investigation By Investing.com - Investing.com Australia
SEC Says Allarity Leaders Hid FDA Issue Before Record Stock Drop - news.bloombergtax.com
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission - GlobeNewswire
Allarity Therapeutics Announces Final Settlement With The U.S. Securities And Exchange Commission - MarketScreener
Allarity Therapeutics Reaches Final Settlement With SEC Over Past Disclosures -March 13, 2025 at 09:18 am EDT - Marketscreener.com
Allarity Therapeutics Announces Final Settlement with SEC Over Previous Disclosures Regarding NDA for Dovitinib - Nasdaq
Allarity Settles SEC Probe: $2.5M Fine Won't Impact Clinical Trials or 2026 Outlook - StockTitan
SEC Says Ex-Allarity Execs Concealed Doomed FDA Approval - Law360
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Grow - Asianet Newsable
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week - MSN
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib - GlobeNewswire
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib and Temozolomide for Recurrent Small Cell Lung Cancer - Nasdaq
Allarity Therapeutics Announces Phase 2 Trial of Stenoparib in Combination with Temozolomide for Recurrent Small Cell Lung Cancer Fully Funded by the US Veterans Administration - The Manila Times
Can This Dual-Action Cancer Drug Overcome Previous PARP Inhibitor Limitations? - StockTitan
Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Up 30.0% in February - Defense World
BDSX Shrinks Loss With Revenue Growth, ALLR Plans $5Mln Share Buyback, What's The Buzz At PTIX? - RTTNews
Allarity Therapeutics (NASDAQ:ALLR) Board Authorizes Share Buyback Program - Defense World
Allarity Therapeutics Announces Board Authorization Of $5 Million Share Repurchase Program - TradingView
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program - GlobeNewswire
Can Allarity's $5M Share Repurchase Signal Hidden Value in Its Cancer Treatment Pipeline? - StockTitan
Allarity Board Authorizes Share Repurchase Program - Nasdaq
ALLR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Allarity Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit - GlobeNewswire
Legal Victory: How Allarity Therapeutics Defeated Its Securities Class Action Without Paying a Dime - StockTitan
Allarity Therapeutics stock hits 52-week low at $0.87 By Investing.com - Investing.com Nigeria
Allarity Therapeutics stock hits 52-week low at $0.87 - Investing.com
Allarity Therapeutics to Begin Enrollment for New Phase 2 - GlobeNewswire
Can This New Ovarian Cancer Drug Challenge the $9B PARP Market? Complete Response Data Emerges - StockTitan
3.01%
자본화:
|
볼륨(24시간):